Business Standard
Saturday, Feb 18, 2012
drived banner
drived banner
  Advanced Search
RSS
Content Guide
Follow us on  
||||Economy & Policy||||| 
 Section Home | News Now | Today's Paper | Features & Analysis | Politics & Public Affairs | Q&A | Columnists | BS Says
Home > Economy & Policy Live Markets | Commodities
 

Economic Survey calls for decontrol of drug prices
Press Trust of India / New Delhi Jul 02, 2009, 16:12 IST

The Economic Survey has called for decontrolling of drug prices and limiting the checks only to essential drugs, which have less than five producers.     

"Drug price control should be limited to essential drugs in which there are less than five producers. All others should be decontrolled," the pre-Budget Survey tabled today in Parliament said.     

The previous government had drafted a National Pharmaceutical Policy that aimed at increasing the national list of essential medicines to 354 from the current 74.     

The drug industry had opposed the move saying it would kill the innovation and the matter was referred to Group of Minister (GoM), but the policy is yet to see the day light.     

The survey meanwhile has lauded the country's pharma industry and said it is taking leaping strides in innovative drug discovery with clinical trials underway in 34 molecules.     

"The Indian pharma industry is taking leaping strides in innovative drug discovery with clinical trials underway in 34 molecules. Consequently, the Indian drug discovery market has grown from $470 million in 2005 to $800 million in 2007," the survey added.

It said the pharma industry has shown high growth — from Rs 1,500 crore turnover in 1980 to Rs 78,000 crore in 2008, garnering about 10 per cent share of global volume production by creating infrastructure and building capacities in complex manufacturing technologies.     

It also listed drug discovery through original and contract research & manufacturing, clinical trials and product specific strategies of acquisition and mergers as other reasons for the sector's success.    

The survey noted that investments in the pharma sector are now expanding to R&D focused outsourcing areas like clinical trials, data management, lead discovery and optimization, pre-clinical drug discovery in combinatorial chemistry and new drug delivery systems.     

It said the pharma sector has attracted FDI of over $1.4 billion during 2000-01 to September 2008, of which $125.3 million inflow was during April-September 2008.     

Besides, India's pharma exports have grown from Rs 6,256 crore in 1998-99 to Rs 30,759 crore in 2008, the Survey added. "Pharma exports have been consistently outstripping the value of corresponding imports in the period 1996-97 up to 2007-08. Exports registered a growth rate of 25 per cent in 2007-08 over 2006-07," it added.     

For the fiscal 2008-09, production of bulk drugs grew 10 per cent at Rs 15,204 crore and formulations were up 22 per cent at Rs 66,796 crore. For 2008, the domestic sector production was Rs 47,241 crore, accounted for by 10,000 small-scale and 300 large and medium units.

New Ipad Application :Business Standard's all new IPad App
Click here to download for free
Arrow Other Stories     
- Wall Street up on Greece, but gains seen limited
- Civic polls: Saffron alliance retains Mumbai, Thane
- MCX awaits trading rules in commodity options, indices
- Govt to provide incentives for electronic chip manufacturing
- Sure to buy French Rafale jets: Indian Air Force
  Read Business news in 
- Now property search gets more exciting than ever before!
- High Growth Business Opportunities in Africa - Register to explore
- Medium-sized businesses are the engines of a smarter planet.
- Office 365 for professionals and small businesses.
- Earn fuel worth Rs.2400 with Citi
- India's No. 1 Property Site. Click here to know more..
- Diseases earlier, Saving Costs, Extending Lives. Know More..
- Get 5% cashback on telephone bills with Citi
- Enjoy the journey as much as the destination. click to know more..
- Exim Bank Conclave on India - Africa Project Partnership. Know more..
- Creating Wealth made simple the SIP way. Know more..
- Only Developer to give a guarantee on time space & rate.
- Buy Your Property with Our Triple Guarantee in India.
- Improve Patient Care & Experience. Click here to know more
- Win a Business Class Ticket to Europe..Know more..
-  Introduce a New Automotive Luxury Car.. know more
Sorry, comments to this story are closed
Latest Messages
SmartInvestor+ E-zine
  Pay Rs.747/- for 3 years and
  get a branded watch FREE

  Subscribe Now
Most Popular
Read
E-Mailed
Commented
   
- The malt of India
- The painter of a dream world
- Umair Javed: A sterile, earnest sea breeze
- Kishore Singh: Keeping up with the Bengali
- The luxury merchants
 
 More  
New Ipad Application
 Business Standard's all new IPad  App
 Click here to download for free
  BS Specials  
    Full coverage of elections in Uttar Pradesh, Punjab, Uttarakhand, Manipur and Goa
  Hot Searches  
 
IRFC bond |  Antrix-Devas |  Rafale fighter |  Junglee |  IPL 5 |  Dhanlaxmi Bank |  Thomas Cook |  TCS |  Sarfaesi Act |  Vodafone |  Aakash tablet |  Sodexo |  Rupee |  Samsung Galaxy Note |  Kingfisher Airlines |  Silver |  Provident Fund |  income tax refund |  Anna Hazare |  iPhone |  Reliance Industries |  SEBI |  BSNL |  BSE |  NSE |  Mukesh Ambani |  Anil Ambani |  Infosys |  Pranab Mukherjee |  Sonia Gandhi |  Rahul Gandhi |  New Pension Scheme |  Reliance |  RBI |  GDP |  Gold |  Ratan Tata |  ICICI |  B-School |  Sensex |  Tax calculator |  Home Loan |  Personal Finance |  inflation |  oil prices |  Barack Obama |   
 
  Member Area Write to the Editor RSS Archives Advanced Search
  Subscribe to BS print product BS e-paper Newsletter Portfolio Tracker
  BS Products BS Hindi BS Motoring BS Books
FOR HOT PRODUCTS
BS Bazaar.com
Home | Markets & Investing | Companies & Industry | Banking & Finance | Economy & Policy | Opinion
Life & Leisure | Management & Marketing | Tech World
About Us | Partner With Us | Code of Conduct | Careers | Advertise with us| Terms & Conditions | Disclaimer | Contact Us